RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Draft Guideline on Labeling Immunoglobulin Products Released by EMA

Draft Guideline on Labeling Immunoglobulin Products Released by EMA

Posted 31 July 2012 | By Alexander Gaffney, RAC 

The European Medicines Agency (EMA) has released a new draft guideline for sponsors of human normal immunoglobulin for subcutaneous and/or intramuscular administration pertaining to the summary of product characteristics (SmPC) required to be submitted to EMA and the European Commission.

The guideline, released 31 July 2012 by EU regulators, notes sponsors of the products will be required to list different SmPCs on the product depending on whether it is intended for subcutaneous administration, intramuscular administration or both.

While several aspects of the harmonized SmPC labeling standard are product-specific-its effect on pediatric populations, excipients used, contraindications, safety issues and preclinical safety data, for example-it presents a largely similar template capable of being used by most immunoglobulin products.

EMA regulators said the guideline will eventually replace an earlier 2002 guideline of a similar name.


Read more:

EMA - Draft guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration

 

© 2022 Regulatory Affairs Professionals Society.